Table 1. Characteristics of refractory MG patients.
| Patient | Antibody status | Gender/Age of onset | Refractory Criteriaa | Previous MG therapiesb |
| 1 | MuSK | F/53 | 1, 2, 3 | Az, PPX |
| 2 | MuSK | F/51 | 1, 2, 3 | Az, IVIG, Pyr |
| 3 | MuSK | F/29 | 1, 2, 3 | IVIG, PPX, Thy |
| 4 | MuSK | F/28 | 1, 3 | Pyr, Thy |
| 5 | MuSK | F/36 | 1, 2, 3 | IVIG, Pyr |
| 6 | MuSK | F/17 | 1, 2, 3 | Az, IVIG, Pyr, Thy |
| 7 | MuSK | F/20 | 1, 2, 3 | P, PPX |
| 8 | MuSK | F/43 | 1, 2, 3 | Cs, IVIG, MM, MTX, Pyr, PPX, Ta, Thy |
| 9 | MuSK | M/62 | 1, 2, 3 | IVIG, MM, P |
| 10 | AChR | M/24 | 2 | P, PPX, Pyr, Thy |
| 11 | AChR | M/59 | 1, 2, 3 | Az, IVIG, P |
| 12 | AChR | M/62 | 1, 2, 3 | Az, IVIG, P, PPX, Thy |
| 13 | AChR | M/28 | 1 | Az, MM, P, Pyr, PPX, Thy |
| 14 | AChR | F/17 | 2, 3 | IVIG, P, PPX, Pyr, Thy |
| 15 | AChR | F/35 | 1, 2, 3 | Az, P, PPX, Thy |
| 16 | AChR | F/48 | 1, 2, 3 | Az, IVIG, P, PPX, Pyr, Thy |
| 17 | AChR | F/50 | 1, 2, 3 | Az, MM, P, PPX, Pyr, Thy |
| 18 | AChR | F/35 | 2 | IVIG, P, Pyr, Thy |
| 19 | AChR | F/35 | 1, 3 | Az, P, Thy |
aRefractory Criteria: (1) inability to lower immunotherapy without clinical relapse, (2) not clinically controlled on immunotherapy regimen, (3) severe side effects from immunotherapy.
bAz, azathioprine; Cs, cyclosporine; IVIG, intravenous immunoglobulin; MM, mycophenolate mofetil; MTX, methotrexate; P, prednisone; PPX, plasma exchange; Pyr, pyridostigmine; Ta, tacrolimus; Thy, thymectomy.